The life of Cipla, the Indian pharma giant, can broadly be divided into three parts: the first 8 decades of altruistic fervour; the second phase-a decade of sharper focus and soaring profits and the third upcoming phase of innovation, new frontiers and possible acquisitions. Steering the second two phases is the company’s global CEO and managing director Umang Vohra. How does a company so deeply rooted in its legacy adapt and scale in a rapidly evolving industry? How does Cipla navigate the seismic shifts in global pharma, from regulatory pressures in the US to the rise of AI-driven drug discovery? What does the future of pharmaceutical innovation hold, and where does Cipla fit into this changing landscape?In this episode, hosts Anirban Chowdhury and Vikas Dandekar sit down with Vohra, to explore Cipla’s past, present and future shaped as much by business acumen as the Bhagvad Gita.
Tune in
You can follow Vikas Dandekar on his Linkedin, Twitter profiles and read his Newspaper Articles.
Check out Vikas Dandekar and Anirban Chowdhury’s other interesting episodes like: India vs TB: Where are we at?, Clearing the Air on HMPV Virus, India’s Dangerous Misuse Of Antibiotics Pt 1 and much more.
You can follow Anirban Chowdhury on his social media: Twitter and Linkedin
Catch the latest episode of ‘The Morning Brief’ on ET Play, The Economic Times Online, Spotify, Apple Podcasts, JioSaavn, Amazon Music and Youtube.
See omnystudio.com/listener for privacy information.
